[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,75,100,124,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053280","phase-3-reck-vs-exparel-in-robotic-nephrectomy-100053280",false,"NCT07092566","R.E.C.K vs Exparel in Robotic Nephrectomy","Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign an IRB-approved informed consent\n2. Age ≥ 18 years at the time of consent.\n3. Planned robotic partial or radical nephrectomy\n\nExclusion Criteria:\n\n1. Determined not to be a candidate to receive R.E.C.K or Exparel per the enrolling investigator\n2. Known pregnancy\n3. Chronic opioid use within 30 days (as per patient report) prior to randomization (defined as ≥ 30 MME\u002Fday)\n4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements as determined by the investigator.\n5. Known allergy to R.E.C.K. and\u002For Exparel","ALL","18 Years",{"count":19,"type":20},170,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.",[26,27,28],"Renal Carcinoma","Nephrectomy \u002F Methods","Pain Management",[30,31],"Analgesics","Nephrectomy","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2025-11-14",{"date":40,"type":20},"2027-10",{"name":42,"class":43},"Wake Forest University Health Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100346136","phase-2-study-of-olaparib-in-metastatic-renal-cell-carcinoma-patients-with-dna-repair-gene-mutations-100346136","NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations","Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID)","ORCHID","Inclusion Criteria:\n\n* Willing and able to provide written informed consent. Provision of informed consent is required prior to any study procedures.\n* Patients aged 18 years of age or older.\n* Histological proof of renal cell carcinoma (both clear cell and non-clear cell allowed).\n* Metastatic (AJCC Stage IV) renal cell carcinoma.\n* Somatic or germline mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L as documented by a clinical CLIA-grade, tissue, saliva or blood-based genetic test.\n* At least one prior treatment with an anti-angiogenic agent or immune checkpoint inhibitor.\n* Any number of prior systemic therapies is allowed (cytokine, anti-angiogenic, mTOR, immune checkpoint blockage or clinical trial).\n* Must have measurable disease as defined by RECIST 1.1 criteria.\n* Participants must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:\n\n  * Hemoglobin ≥ 10.0 g\u002FdL with no blood transfusion in the past 28 days\n  * Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL\n  * Platelet count ≥ 100 x 10\\^9\u002FL\n  * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)\n  * Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) \u002F Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional ULN unless liver metastases are present in which case they must be ≤ 5 x ULN.\n\nNote: Patients with elevations in bilirubin, AST, or ALT should be thoroughly evaluated for the etiology of this abnormality prior to entry and patients with evidence of viral infection should be excluded.\n\n* Patients must have a creatinine clearance ≥ 40 mL\u002Fmin calculated by Cockroft-Gault formula or 24 hour urine test.\n* ECOG PS ≤ 1.\n* Participants must have a life expectancy ≥ 16 weeks.\n* Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.\n\nPostmenopausal is defined as:\n\n* Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments.\n* Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50 years old.\n* Radiation-induced oophorectomy with last menses \\> 1 year ago.\n* Chemotherapy-induced menopause with \\> 1 year interval since last menses.\n* Surgical sterilization (bilateral oophorectomy or hysterectomy).\n* Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.\n\nExclusion Criteria:\n\n* Other malignancy unless curatively treated with no evidence of disease for ≥ 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma. Patients with a history of localized triple negative breast cancer may be eligible, provided they completed their adjuvant chemotherapy \\> 3 years prior to registration, and that the patient remains free of recurrent or metastatic disease.\n* Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.\n* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Breast feeding women.\n* Use of any prohibited concomitant medications within the prior 2 weeks.\n* Involvement in the planning and\u002For conduct of the study (applies to both AstraZeneca staff and\u002For staff at the study site).\n* Participation in another clinical study with an investigational product during the last 2 weeks.\n* Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.\n* Any previous treatment with PARP inhibitor, including olaparib.\n* Resting ECG with QTc \\> 500 ms and\u002For indication of uncontrolled cardiac conditions, as judged by the investigator (e.g. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, electrolyte disturbances, etc.), or patients with congenital and\u002For family history of long QT syndrome.\n* Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks. During the study, if co-administration of a strong or moderate inhibitor is required because there is no suitable alternative medication, exception to this criterion may be allowed with a suitable dose reduction of olaparib.\n* Concomitant use of known strong CYP3A inducers (e.g. phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for phenobarbital or enzalutamide and 3 weeks for other agents.\n* Persistent toxicities (\\> Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia.\n* Patients with myelodysplastic syndrome (MDS)\u002Facute myeloid leukemia (AML) or with features suggestive of MDS\u002FAML.\n* Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n* Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.\n* Unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n* Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).\n* Known hypersensitivity to olaparib or any of the excipients of the product.\n* Known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.\n* No packed red blood cells and\u002For platelet transfusions within the last 28 days prior to study entry.","120 Years",{"count":55,"type":20},20,[57],"PHASE2","Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy. Must have measurable disease on CT imaging per RECIST 1.1 criteria.",[60,61,62,26,63],"Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Kidney Cancer","Kidney Cancer Metastatic",[65],"Olaparib","2026-03-24",{"date":68,"type":36},"2026-03-30",{"date":70,"type":36},"2019-06-03",{"date":72,"type":20},"2028-03",{"name":74,"class":43},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100623513","phase-2-pre-neoshift-rcc-neoadjuvant-hif-inhibitor-immunotherapy-in-rcc-100623513","NCT07397611","Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC","PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOSHIFT-RCC)","Inclusion Criteria:\n\n* Adult patients age ≥ 18 years.\n* Histologically confirmed diagnosis of ccRCC by a core-needle biopsy. Patients who have not had prior biopsy may undergo screening if they have suspected RCC but can only proceed to registration if ccRCC (any component) is confirmed on the pre-treatment study biopsy.\n* Stage cT2 RCC with grade 4 or sarcomatoid features, ≥cT3 Nx RCC, or cTany N+ RCC disease for which partial or radical nephrectomy is planned. For clinical staging, a kidney MRI is highly preferred over a CT Abdomen.\n* Participants must have measurable disease i.e. a primary renal tumor that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan or MRI. See Section 11 (Measurement of Effect) for the evaluation of measurable disease.\n* Participants must be planned for surgical resection of their primary renal tumor.\n* ECOG performance status of 0-1.\n* Participants must have adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:\n\n  1. Absolute neutrophil count ≥ 1.0 × 10\\^9\u002FL without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection.\n  2. Platelet count ≥ 100 × 10\\^9\u002FL without transfusion within 2 weeks of screening laboratory sample collection.\n  3. Hemoglobin ≥ 10.0 g\u002FdL (or 6.2 mmol\u002FL).\n  4. Aspartate transaminase (AST) ≤ 2.5 × upper limit of normal (ULN)\n  5. Alanine aminotransferase (ALT) ≤ 2.5 × ULN.\n  6. Bilirubin ≤ 1.5 × ULN (except participants with Gilbert syndrome who must have total bilirubin \\\u003C 3.0 mg\u002FdL).\n  7. Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.\n  8. Ambulatory oxygen saturation \\>92% on room air at time of screening.\n  9. Serum albumin ≥ 2.8 g\u002Fdl.\n  10. INR ≤ 1.5.\n  11. Calculated creatinine clearance ≥ 40 mL\u002Fmin (≥ 0.67 mL\u002Fsec) using the Cockcroft-Gault equation:\n\n      ---Males: (140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72)\n\n      ---Females: \\[(140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72)\\] × 0.85\n* No exercise-induced desaturation on a 6-minute walk test, defined as a blood oxygen saturation by pulse oximetry ≤ 88%.\n* No active clinical pneumonitis at screening.\n* No medical history of severe chronic obstructive pulmonary disease (COPD)\n* Screening echocardiogram or MUGA scan must demonstrate a left ventricular ejection fraction (LVEF) greater than the institutional lower limit of normal (LLN).\n* Negative serum pregnancy test at screening for women of childbearing potential. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.\n* Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Through 7 days after the last dose of casdatifan and 120 days after the last dose of zimberelimab for women of childbearing potential and for men\n* Ability to understand and the willingness to sign a written informed consent document.\n* Ability to swallow tablets.\n\nExclusion Criteria:\n\n* Any prior systemic therapy for treatment of renal cell carcinoma.\n* Any radiation therapy within 4 weeks before the first dose of study treatment.\n* Any clear evidence of distant metastases. Enlarged lymph nodes that are planned to be removed during nephrectomy are permitted.\n* Clinical pneumonitis or concern for inflammatory lung disease at time of screening.\n* Any complementary medications (eg, herbal supplements or traditional Chinese medicines) with the intention to treat the disease under study within 2 weeks before first dose of study treatment.\n* Other prior malignancy active within the previous year except for locally curable cancers (\\>90%) that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or Gleason 6 prostate cancer. Also, indolent malignancies, including but not limited to early-stage chronic lymphocytic leukemia and follicular lymphoma, that don't require anti-cancer treatment, could be allowed after discussion with the medical monitor.\n* QTc ≥ 480 msec using Fridericia's correction (QTcF) (based on an average of triplicate recordings).\n* Malabsorption condition that would alter the absorption of orally administered medications.\n* Patient has had any major cardiovascular event within 6 months prior to study drug administration including but not limited to myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic event, pulmonary embolism, clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or New York Heart Association Class III or IV heart failure.\n* The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 2 or greater, unstable angina pectoris, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes).\n\nii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 150 mm Hg systolic or \\> 95 mm Hg diastolic despite optimal antihypertensive treatment.\n\niii. Any history of stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant ischemic event within 12 months before first dose of study treatment.\n\niv. Clinically significant pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous or non-CVA\u002FTIA arterial thromboembolic events within 3 months before to first dose of study treatment. Thrombus felt due to tumor and not a bland thrombus is permitted.\n\nNote: Subjects with a diagnosis of DVT\u002FPE due to bland thrombus need to be asymptomatic and have at least 4 weeks of anticoagulation before first dose of study treatment.\n\nv. Any history of myocarditis.\n\nb. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. Tumors invading the GI-tract from external viscera. ii. Active and symptomatic peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis.\n\niii. Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months unless the cause of obstruction is definitively managed and subject is asymptomatic.\n\niv. Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before the first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before the first dose of study treatment.\n\nv. Known gastric or esophageal varices. vi. Ascites requiring drainage within 28 days prior to initiation of protocol therapy c. Autoimmune disease that has been symptomatic or required treatment with 1mg\u002Fkg of corticosteroids within the past two years from the date of randomization. Diabetes mellitus and thyroid auto-immune diseases are excluded.\n\nd. Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (eg, contrast allergy) is also allowed. Corticosteroids given as short course premedication is acceptable.\n\n* Other clinically significant disorders that would preclude safe study participation.\n\n  1. Active infection requiring systemic treatment. Note: Prophylactic antibiotic treatment is allowed.\n  2. Infection with acute or chronic hepatitis B or C with detectable viral load, human immunodeficiency virus (HIV) infection with detectable viral load or acquired immunodeficiency syndrome (AIDS)-related illness.\n  3. Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n  4. Pharmacologically uncompensated, symptomatic hypothyroidism.\n  5. Moderate to severe hepatic impairment (Child-Pugh B or C).\n  6. History of solid organ or allogeneic stem cell transplant.\n* Major surgery (as defined in Appendix B) within 4 weeks prior to first dose of study treatment. Minor surgery (eg, simple excision, tooth extraction) within 7 days before the first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to the first dose of study treatment.\n* Patients who are receiving treatment with strong CYP3A4 inhibitors and inducers should have a washout period of 28 days or 5 half-lives of the concerning medicine prior to starting casdatifan.\n* History of psychiatric illness, mental condition or substance use disorders that are likely to interfere with ability to comply with protocol requirements or give informed consent.\n* Use of any live vaccines against infectious diseases within 28 days of first dose of study drug.\n* Current breastfeeding.\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n* Any use of supplemental or intermittent oxygen therapy.\n* Other conditions, which in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study.",{"count":83,"type":20},32,[57],"The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC).\n\nThe names of the study drugs involved in this study are:\n\n* Casdatifan (a type of HIF-2α inhibitor)\n* Zimberelimab (a type of monoclonal antibody)",[60,62,87,26],"Kidney Neoplasm",[60,62,87,26,89],"ccRCC","2026-03-18",{"date":92,"type":36},"2026-03-20",{"date":94,"type":36},"2026-03-09",{"date":96,"type":20},"2029-09-30",{"name":98,"class":43},"Dana-Farber Cancer Institute",3,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100628731","radiofrequency-ablation-multicenter-observational-study-in-renal-oncology-patients-100628731","NCT07465458","Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients","RASROP-003","Patient selection criteria will be those typically established by each participating center t with T1a primary renal tumors for which a Multidisciplinary Tumor Board has indicated as candidates for treatment with radiofrequency ablation.I\n\nInclusion Criteria:\n\n* Age ≥18 years\n* Signed informed consent approved by the Ethics Committee prior to the ablation procedure.\n* RCC in stage T1a (size \\\u003C4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation\n* Absence of comorbidities that contraindicate treatment\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 at baseline screening.\n\nExclusion Criteria:\n\n* No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.",{"count":108,"type":20},226,"12 Months","OBSERVATIONAL","This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.",[26],"NOT_YET_RECRUITING","2026-03-12",{"date":116,"type":36},"2026-03-16",{"date":118,"type":20},"2026-03",{"date":120,"type":20},"2028-06",{"name":122,"class":43},"Humanitas Hospital, Italy",10,{"id":125,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":24,"conditions":128,"keywords":129,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":135,"locationsCount":44},"100600059",{"count":19,"type":20},[23],[26,27,28],[30,31],"2026-01-16",{"date":132,"type":36},"2026-01-20",{"date":38,"type":36},{"date":40,"type":20},{"name":42,"class":43},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":44},"100538407","comparison-of-outcomes-of-multiple-platforms-for-assisted-robotic-kidney-compar-k-100538407","NCT06290427","Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)","Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney","COMPAR-K","Inclusion Criteria:\n\n* patient aged between 18 and 90 years old;\n* patient with localized kidney tumor suitable for partial nephrectomy;\n* patient able to understand and sign the informed consent;\n* patient compliance with the follow-up program.\n\nExclusion Criteria:\n\n* patient who do not fall within the inclusion age range;\n* patient not suitable for partial nephrectomy;\n* patient unable to understand and sign the informed consent;\n* patient unable to follow the monitoring program;\n* patient refusal to participate to the study.","90 Years",{"count":146,"type":20},30,[148],"NA","The Urology Unit of AOUI Verona proposes a clinical study aimed at a preliminary evaluation of postoperative complications specifically focused on robotic partial nephrectomy (RAPN) procedures using two currently available platforms:\n\n* DaVinci®;\n* Hugo®.\n\nThe questions it aims to answer are:\n\nDoes the estimation of the post-operative complications suggest something? Are differences (intra- and post-operative, oncological, functional, technical, and economic) among the three intervention approaches observable?\n\nParticipants will be invited to join one of these two experimental group:\n\n1. surgery with the DaVinci platform;\n2. surgery with the Hugo platform.",[26],[152,153,154,155,156],"Robotic-assisted surgery","Partial Nephrectomy","Multiple surgical platforms","Postoperative complications","Operative outcomes","2025-01-02",{"date":159,"type":36},"2025-01-03",{"date":161,"type":36},"2024-02-01",{"date":163,"type":20},"2025-06",{"name":165,"class":43},"Azienda Ospedaliera Universitaria Integrata Verona"]